# The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects

> **NCT02581020** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 344 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02581020
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-14
- **Primary completion:** 2020-12-08
- **Final completion:** 2020-12-08
- **Target enrollment:** 344 (ACTUAL)
- **Last updated:** 2021-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581020, "The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02581020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*